A Pharmacokinetic Study of VCT220 With Moderate Renal Impairment Patients

Inclusion Criteria: * Male or female subjects aged 18 to 75 years * Body mass index (BMI) between 18.5 and 32.0 kg/m² * Able and willing to provide written informed consent * Willing to comply with contraception requirements * Moderate renal impairment group * Absolute eGFR ≥30 and \<60 mL/min * Diagnosis of chronic kidney disease for ≥3 months with stable renal function * Normal renal function group: Absolute eGFR ≥90 and \<130 mL/min Matched to moderate renal impairment subjects by sex, age (±10 years), and BMI (±10%) Exclusion Criteria: * History of hypersensitivity to GLP-1 receptor agonists or study drug components * History of hypoglycemia * History or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 * History of pancreatitis * Clinically significant cardiovascular, hepatic, gastrointestinal, neurological, hematologic, endocrine, or psychiatric disease * Use of prohibited medications affecting drug metabolism prior to dosing * Positive tests for hepatitis B, hepatitis C, HIV, or syphilis * Pregnant or breastfeeding women